Annual report pursuant to Section 13 and 15(d)

Cover

v3.24.3
Cover - USD ($)
 12 Months Ended
Jun. 30, 2024
Sep. 20, 2024
Dec. 31, 2023
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Jun. 30, 2024    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2024    
Current Fiscal Year End Date --06-30    
Entity File Number 001-40388    
Entity Registrant Name ANEBULO PHARMACEUTICALS, INC.    
Entity Central Index Key 0001815974    
Entity Tax Identification Number 85-1170950    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 1017 Ranch Road 620 South    
Entity Address, Address Line Two Suite 107    
Entity Address, City or Town Lakeway    
Entity Address, State or Province TX    
Entity Address, Postal Zip Code 78734    
City Area Code (512)    
Local Phone Number 598-0931    
Title of 12(b) Security Common Stock    
Trading Symbol ANEB    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period false    
Entity Shell Company false    
Entity Public Float     $ 9,468,006
Entity Common Stock, Shares Outstanding   25,933,217  
Documents Incorporated by Reference None.    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Listing, Par Value Per Share $ 0.001    
Auditor Firm ID 274    
Auditor Opinion [Text Block] We have audited the accompanying balance sheets of Anebulo Pharmaceuticals, Inc. (the “Company”) as of June 30, 2024 and 2023, and the related statements of operations, stockholders’ equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2024 and 2023, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.    
Auditor Name EISNERAMPER LLP    
Auditor Location Iselin, New Jersey